Pharmacy growth drives a raised full-year outlook
- In Q2 2026, Pharmacy Solutions revenue grew 22.1% to $3.4 billion, making it the clear growth engine.
- Specialty and Infusion script growth hit 31% in Q2, easily outpacing the broader market.
- Management raised full-year 2026 adjusted EBITDA guidance to a range of $820 million to $845 million.
- Company leverage fell further to 2.15x, easing concerns about the balance sheet.
- The primary headwind is a roughly $200 million revenue impact expected this year from the Inflation Reduction Act.
A cleaner company, a higher bar
BrightSpring has successfully shifted from a balance sheet repair story to an execution story. Following the Community Living sale earlier this year, leverage has dropped to 2.15x. This gives management the flexibility to pursue small local acquisitions and focus on the core specialty pharmacy business.
The bull case relies on Pharmacy Solutions continuing its rapid expansion. Specialty and Infusion scripts grew 31% year over year in Q2 2026, driving a top-line beat. Management also raised its 2026 adjusted EBITDA target to a range of $820 million to $845 million, showing confidence in near-term demand.
The bear case centers on pricing and profit margins. Changes tied to the Inflation Reduction Act are expected to create a roughly $200 million revenue drag in 2026 for the Home and Community pharmacy business. Investors must weigh rapid script growth against these ongoing pricing pressures.
While the operational story is stronger than ever, the market price already demands high performance. Investors should watch whether the company can maintain its rapid specialty pharmacy growth while absorbing new reimbursement rules.
Care at home, paid by insurers
BrightSpring generates revenue by serving high-need patients in lower-cost settings, most often at home. Government programs and private insurers pay the company for pharmacy, home health, hospice, rehab, and related care services.
The company aims to stand out by linking pharmacy and care services inside a single system. The idea is that better medication support and care coordination can reduce hospital visits, which makes BrightSpring more valuable to payers.
This model depends heavily on scale. More patients, higher pharmacy volume, and more local branches allow the company to spread fixed costs across a larger base. This is why small, targeted acquisitions matter so much when they add new local markets.
The main vulnerability is reimbursement rates. If payers lower what they will pay for specialty drugs or home health, BrightSpring needs even higher volume just to keep its profit steady.
What BrightSpring sells
Specialty Pharmacy
This is the largest growth driver inside Pharmacy Solutions. It serves patients using complex, often expensive medicines, including oncology therapies.
Infusion Pharmacy
Infusion services help patients receive drugs outside the hospital. Specialty and Infusion scripts grew 31% year over year in Q2 2026.
Home and Community Pharmacy
This business supports patients who need ongoing medication management. It adds recurring revenue but faces roughly $200 million in pricing headwinds this year.
Home Health and Hospice
These services sit in Provider Services. The acquisition of branches from Amedisys and LHC recently expanded this division.
Rehabilitation Services
Rehab services help patients recover after illness or surgery. This fits the company focus on providing care outside high-cost hospital settings.
Care Coordination
Care coordination connects pharmacy and provider services. If it lowers hospitalizations, it helps BrightSpring win more payer relationships.
The mix is mostly pharmacy
Segment mix is from the three months ended June 30, 2026. Pharmacy Solutions was roughly 88% of revenue, making the company highly sensitive to specialty drug volumes.
What could break the thesis
Specialty script growth slows
High impact · Medium oddsThe bull case depends on Specialty and Infusion scripts staying strong. Q2 2026 growth was 31% year over year. If that growth slows sharply against tough comparisons, investors may question the premium valuation.
Reimbursement pressure rises
High impact · Medium oddsBrightSpring is paid by government programs and private insurers. Changes tied to the Inflation Reduction Act are expected to create a roughly $200 million revenue headwind in 2026. Further pricing pressure could shrink profit margins.
Amedisys and LHC integration misses
Medium impact · Medium oddsProvider Services grew 30.3% year over year in Q2 2026, helped by acquired Amedisys and LHC branches. Management now expects roughly $35 million of 2026 EBITDA contribution from those assets. The risk is that branch integration stalls or costs more than planned.
Acquisition discipline slips
Medium impact · Low oddsWith leverage down to 2.15x, management has room to pursue more acquisitions. That helps growth if deals are well priced, but it hurts shareholders if the company overpays or buys assets that are hard to integrate.
In one breath
What does BrightSpring Health Services do?
BrightSpring provides healthcare services for complex patients, often in the home. Its main businesses are specialty pharmacy, infusion pharmacy, home health, hospice, rehab, and care coordination.
Why is Pharmacy Solutions so important for BTSG?
Pharmacy Solutions generated about 88% of Q2 2026 revenue. Its script volume grew 31% year over year, making it the primary engine for the company's overall growth.
Did the Community Living divestiture happen?
Yes. BrightSpring completed the Community Living divestiture on March 30, 2026. Since then, company leverage has fallen to 2.15x.
What should investors watch next?
The biggest items are achieving the raised 2026 adjusted EBITDA guidance of $820 million to $845 million, sustaining specialty script growth, and managing the new Medicare pricing rules.
